No Prescription |
 |
 | ||
|
Rosiglitazone Avandia |
|
| ||
No Prescription » Prescription Drugs 14 » Rosiglitazone Avandia Rosiglitazone ((ROS-e-glit-a-zone)) is used to treat a certain type of diabetes mellitus (sugar diabetes) called type 2 diabetes. It may be used alone or with another type of diabetes medicine such as metformin insulin a sulfonylurea or sulfonylurea plus metformin. Rosiglitazone is used for: Controlling blood sugar levels along with diet and exercise in patients with type 2 diabetes. Rosiglitazone is an oral diabetes medicine that help control blood sugar levels. Rosiglitazone is for people with type 2 diabetes who do not use daily insulin injections. This medication is not for treating type 1 diabetes. Rosiglitazone maleate is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. Rosiglitazone is used in the management of type 2 diabetes mellitus (also known as non-insulin-dependent diabetes mellitus [NIDDM] or adult-onset diabetes). Buy Rosiglitazone Avandia and other Prescription Drugs 14 products online at Medstore. 3752
About Rosiglitazone Avandia: Product Type: Prescription Drugs 14 Rosiglitazone ( Avandia Generic Rosiglitazone ) Rosiglitazone (Avandia Generic Rosiglitazone) Avandia Generic Rosiglitazone 4mg Bottle ( 100 Tabs ) Avandia Generic Rosiglitazone Rosiglitazone
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
